» Articles » PMID: 37080957

A Tissue Specific-infection Mouse Model of SARS-CoV-2

Overview
Journal Cell Discov
Date 2023 Apr 20
PMID 37080957
Authors
Affiliations
Soon will be listed here.
Abstract

Animal models play crucial roles in the rapid development of vaccines/drugs for the prevention and therapy of COVID-19, but current models have some deficits when studying the pathogenesis of SARS-CoV-2 on some special tissues or organs. Here, we generated a human ACE2 and SARS-CoV-2 N knockin mouse line that constitutively expresses human ACE2 and specifically expresses SARS-CoV-2 N gene induced by Cre-recombinase. By crossing with Cre transgenic lines allowing for lung-specific and constitutive expression, we generated lung-specific (Sftpc-hACE2-N) and constitutive SARS-CoV-2 N (EIIa-hACE2-N) expressing mice. Upon intranasal infection with a SARS-CoV-2 GFP/ΔN strain which can only replicate in SARS-CoV-2 N expressed cells, we demonstrated that both the Sftpc-hACE2-N and EIIa-hACE2-N mice support viral replication. Consistent with our design, viral replication was limited to the lung tissues in Sftpc-hACE2-N mice, while the EIIa-hACE2-N mice developed infections in multiple tissues. Furthermore, our model supports different SARS-CoV-2 variants infection, and it can be successfully used to evaluate the effects of therapeutic monoclonal antibodies (Ab1F11) and antiviral drugs (Molnupiravir). Finally, to test the effect of SARS-CoV-2 infection on male reproduction, we generated Sertoli cell-specific SARS-CoV-2 N expressed mice by crossing with AMH-Cre transgenic line. We found that SARS-CoV-2 GFP/ΔN strain could infect Sertoli cells, led to spermatogenic defects due to the destruction of blood-testis barrier. Overall, combining with different tissue-specific Cre transgenic lines, the human ACE2 and SARS-CoV-2 N line enables us to evaluate antivirals in vivo and study the pathogenesis of SARS-CoV-2 on some special tissues or organs.

Citing Articles

An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo.

Li Y, Tan X, Deng J, Liu X, Liu Q, Zhang Z Virol Sin. 2024; 39(3):447-458.

PMID: 38548102 PMC: 11280264. DOI: 10.1016/j.virs.2024.03.009.


Generation of a humanized mAce2 and a conditional hACE2 mouse models permissive to SARS-COV-2 infection.

Song I, Washington M, Leynes C, Hsu J, Rayavara K, Bae Y Mamm Genome. 2024; 35(2):113-121.

PMID: 38488938 DOI: 10.1007/s00335-024-10033-8.

References
1.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

2.
Ju X, Zhu Y, Wang Y, Li J, Zhang J, Gong M . A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathog. 2021; 17(3):e1009439. PMC: 7990224. DOI: 10.1371/journal.ppat.1009439. View

3.
Li N, Tang E, Cheng C . Regulation of blood-testis barrier by actin binding proteins and protein kinases. Reproduction. 2015; 151(3):R29-41. PMC: 4780571. DOI: 10.1530/REP-15-0463. View

4.
Sheahan T, Sims A, Zhou S, Graham R, Pruijssers A, Agostini M . An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020; 12(541). PMC: 7164393. DOI: 10.1126/scitranslmed.abb5883. View

5.
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View